Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice.

Neuroscience letters - 9 Jan 2009

Popiel H Akiko, Nagai Yoshitaka, Fujikake Nobuhiro, Toda Tatsushi

Abstract excerpt

The polyglutamine (polyQ) diseases are neurodegenerative diseases caused by proteins with an abnormally expanded polyQ stretch, which triggers abnormal aggregation of these proteins in the brain. We previously showed that the polyQ-binding peptide QBP1 inhibits polyQ aggregation, and further that administration of QBP1 fused with a protein transduction domain (PTD) suppresses polyQ-induced neurodegeneration in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Weight
Share to Injections, Intraventricular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Transgenic

Share to Neurodegenerative Diseases

Share to Neurons

Share to Oligopeptides

Share to Peptides

Share to Recombinant Fusion Proteins

Source

Identifiers

PMID: 18603372
DOI: 10.1016/j.neulet.2008.06.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice.PMID 18603372Read ↗

Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism.Semantic proximity Read ↗

Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine DiseasesSemantic proximity Read ↗

Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Semantic proximity Read ↗

A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1.Semantic proximity Read ↗

Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.Semantic proximity Read ↗

Large-Scale Screen for Modifiers of Ataxin-3-Derived Polyglutamine-Induced Toxicity in DrosophilaSemantic proximity Read ↗

PQBP-1 transgenic mice show a late-onset motor neuron disease-like phenotype.Semantic proximity Read ↗

Mouse Models of Polyglutamine Diseases: Review and Data Table. Part ISemantic proximity Read ↗

Therapeutic suppression of proteolipid protein rescues Pelizaeus-Merzbacher Disease in miceSemantic proximity Read ↗

The β-turn-supporting motif in the polyglutamine binding peptide QBP1 is essential for inhibiting huntingtin aggregation.Semantic proximity Read ↗

Delivery of BACE1 siRNA mediated by TARBP-BTP fusion protein reduces β-amyloid deposits in a transgenic mouse model of Alzheimer’s DiseaseSemantic proximity Read ↗

A restricted level of PQBP1 is needed for the best longevity of Drosophila.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.